Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

OP003: Increased risk of acute arterial events in young patients with severely active inflammatory bowel disease: a nationwide French cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Kirchgesner J.*1,2, Beaugerie L.1, Carrat F.3,4, Nyboe Andersen N.5, Jess T.5,6, Schwarzinger M.7,8 For the BERENICE Study Group

1Saint-Antoine Hospital, AP-HP, Gastroenterology, Paris, France 2INSERM, University Paris 06, UMR S 1136, Paris, France 3Hopital Saint Antoine, Department of Public Health, Paris, France 4INSERM, University Paris 06, UMR S 1136, Paris, France 5Statens Serum Institute, Department of Epidemiology Research, Copenhagen, Denmark 6Frederiksberg Hospital, Institute of Preventive Medicine, Frederiksberg, Denmark 7INSERM, UMR 1137, Paris, France 8THEN, Translational Health Economics Network, Paris, France

OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Le Bourhis L.1, Corraliza A.2, Auzolle C.1, Ricart E.2, Hawkey C.3, Lindsay J.O.4, Clark M.3, Rogler G.5, Satsangui J.6, Haller D.7, Panes J.2, Salas A.2, Allez M.*1

1Hôpital Saint-Louis INSERM, U1160 – Intestinal Immunity in Inflammation and Cancer, Paris, France 2IDIBAPS, Hospital Clínic, Gastroenterology, Barcelona, Spain, Barcelona, Spain 3University of Nottingham, Gastroenterology, Nottingham, United Kingdom 4Barts and The London, Queen Mary University of London, Centre for Immunology, The Blizard Institute, London, United Kingdom 5University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Swaziland 6Western General Hospital, Gastrointestinal Unit, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom 7Technical University Munich, Department of Nutrition and Immunology, Freising, Germany

OP005: The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the efficacy and safety across ItalyECCO '17 Barcelona
Year: 2017
Authors:

Guidi L.1, Fiorino G.*2, Variola A.3, Manetti N.4, Fries W.5, Rizzuto G.6, Bossa F.7, Cappello M.8, Biancone L.9, D'Incà R.10, Cantoro L.11, Castiglione F.12, Principi M.13, Annunziata M.L.14, Di Girolamo M.15, Terpin M.M.16, Cortelezzi C.C.17, Costa F.18, Amato A.19, Di Sabatino A.20, Saibeni S.21, Meucci G.22, Petruzzellis C.23, Tari R.24, Gugliemi F.W.25, Armuzzi A.26, Danese S.2, Geccherle A.3, Rogai F.4, Ventra A.5, Orlando A.6, Andriulli A.7, Scrivo B.8, Troncone E.9, Caccaro R.10, Kohn A.11, Nardone O.12, Annese V.27

1Complesso Integrato Columbus, Fondazione Policlinico Gemelli Universita' Cattolica, Internal Medicine and Gastroenterology, Rome, Italy 2Humanitas Research Hospital and University, Gastroenterology and IBD Center, Rozzano, Italy 3Sacro Cuore Don Calabria Hospital, Gastroenterology and Hepatology, Negrar, Italy 4AOU Careggi, DEA, Gastroenterology, Florence, Italy 5University of Messina, Clinical Unit for Chronic Bowel Disorders, Messina, Italy 6Riuniti Villa Sofia - Cervello Hospital, Internal Medicine 2, Palermo, Italy 7IRCCS-CSS Hospital, Gastroenterology, San Giovanni Rotondo, Italy 8University Hospital, Gastroenterology, Palermo, Italy 9Tor Vergata, Gastroenterology, Roma, Italy 10University of Padova, Gastroenterology, Padova, Italy 11S. Camillo-Forlanini Hospital, Gastroenterology, Rome, Italy 12Federico II University, Gastroenterology, Naples, Italy 13University Bari, Gastroenterology, Bari, Italy 14IRCCS Policlinico, Gastroenterology & Digestive Endoscopy Unit, San Donato, Milano, Italy 15University Hospital, Gastroenterology, Modena, Italy 16AO Hospital, Gastroenterology and Endoscopy, Legnano, Italy 17AOU di Circolo Fondazione Macchi, Gastroenterology, Varese, Italy 18AOUP, Gastroenterology, Pisa, Italy 19Ospedale Valduce, Gastroenterology, Como, Italy 20S.Matteo Hospital Foundation, University of Pavia, First Department of Medicine, Pavia, Italy 21ASST Rhodense, Gastroenterology Unit, Rho, Italy 22S. Giuseppe Hospital, Gastroenterology, Milano, Italy 23Poliambulanza Hospital, Gastroenterology and Digestive Endoscopy, Brescia, Italy 24AOU Maggiore, Gastroenterology, Novara, Italy 25S. Pellegrino Hospital, Gastroenterology, Trani, Italy 26Complesso Integrato Columbus - Catholic University, Internal Medicine and Gastroenterology, Rome, Italy 27Valiant Clinic, Gastroenterology, Dubai, United Arab Emirates

OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trialECCO '17 Barcelona
Year: 2017
Authors:

Pouillon L.*1, Ferrante M.1, Van Assche G.1, Rutgeerts P.1, Noman M.1, Vande Casteele N.2, Gils A.3, Vermeire S.1

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 2University of California San Diego, Department of Medicine, La Jolla, CA, United States 3University of Leuven, Department of Pharmaceutical Sciences, Leuven, Belgium

OP007: A multi-centre double blind randomised placebo-controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitisECCO '17 Barcelona
Year: 2017
Authors:

Lawrance I.C.*1,2, Baird A.1, Lightowler D.2, Radford-Smith G.3, Andrews J.M.4, Connor S.5

1University of Western Australia, Medicine and Pharmacology, Perth, Australia 2Saint John of God Hospital, Centre for Inflammatory Bowel Diseases, Subiaco, Australia 3University of Queensland School of Medicine, IBD Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia 4University of Adelaide, School of Medicine, Adelaide, Australia 5University of NSW, Medicine, South Western Sydney Clinical School, Sydney, Australia

OP008: An innovative treatment for refractory perianal fistulas in Crohn's disease: local micro reinjection of autologous fat and adipose derived stromal vascular fractionECCO '17 Barcelona
Year: 2017
Authors:

Serrero M.*1, Philandrianos C.2, Visee C.3, Veran J.2, Orsoni P.3, Sabatier F.2, Grimaud J.-C.1

1Hopital Nord, Gastroenterology, Marseille, France 2Aix-Marseille, Marseille, France 3Hopital Nord, Visceral Surgery, Marseille, France

OP009: Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's disease: 52-week results of a phase III randomised controlled trialECCO '17 Barcelona
Year: 2017
Authors:

Panes J.*1, García-Olmo D.2, Van Assche G.3, Colombel J.-F.4, Reinisch W.5, Baumgart D.C.6, Nachury M.7, Ferrante M.3, Kazemi-Shirazi L.5, Grimaud J.C.8, de la Portilla F.9, Goldin E.10, Richard M.P.11, Diez M.C.11, Danese S.12

1Hospital Clínic de Barcelona, Dept of Gastroenterology, Barcelona, Spain 2Hospital U. Fundaciόn Jiménez-Díaz, Madrid, Spain 3University Hospitals Leuven, KU Leuven, Leuven, Belgium 4Icahn School of Medicine at Mount Sinai, New York, United States 5Medical University of Vienna, Vienna, Austria 6Charité Medical School - Humboldt-University of Berlin, Berlin, Germany 7CHU Lille, Lille, France 8Hôpital Nord, Marseille, France 9Hospital Virgen del Rocío, Sevilla, Spain 10Sharee Zedek MC, Jerusalem, Israel 11TiGenix, Madrid, Spain 12Istituto Clinico Humanitas, Milano, Italy

OP010: Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 yearsECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.1, Rutgeerts P.2, Gasink C.3, Jacobstein D.3, Gao L.-L.3, Johanns J.3, Sands B.4, Hanauer S.B.5, Targan S.6, Ghosh S.7, de Villiers W.J.S8, Colombel J.-F.4, Feagan B.G.*9

1University of California San Diego, La Jolla, United States 2University Hospital, Gasthuisberg, Leuven, Belgium 3Janssen Research & Development, LLC, Spring House, United States 4Icahn School of Medicine at Mt Sinai, New York, United States 5Northwestern University Feinberg School of Medicine, Chicago, United States 6Cedars-Sinai Medical Center, Los Angeles, United States 7University of Birmingham, Birmingham, United Kingdom 8University of Stellenbosch, Stellenbosch, South Africa 9Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ont., Canada

OP011: Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY studyECCO '17 Barcelona
Year: 2017
Authors:

Peyrin-Biroulet L.*1, Feagan B.G.2, Mansfield J.3, Rubin D.T.4, Arulmani U.5, Maciuca R.5, Tyrrell H.6, Thommes J.5, Tole S.6

1Université de Lorraine, Vandœuvre-lès-Nancy, France 2University of Western Ontario, London, Canada 3Newcastle University, Newcastle upon Tyne, United Kingdom 4University of Chicago Medicine, Chicago, United States 5Genentech, South San Francisco, United States 6Roche, Welwyn Garden City, United Kingdom

OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with ulcerative colitis undergoing (procto)colectomy with ileal pouch-anal anastomosisECCO '17 Barcelona
Year: 2017
Authors:

Ferrante M.*1, Schils N.1, De Buck van Overstraeten A.2, Vermeire S.1, Van Assche G.1, Wolthuis A.2, D'Hoore A.2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 2University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium

OP013: Disease management and outcomes of patients with Crohn's disease at high risk of recurrence. Results from PRACTICROHN studyECCO '17 Barcelona
Year: 2017
Authors:

Iborra M.*1, Martín Arranz M.D.2, Domènech E.3, García V.4, Gutiérrez A.5, Barreiro-de Acosta M.6, Cea-Calvo L.7, Romero C.7, Juliá B.7

1Servicio de Gastroenterologia, Hospital La Fe, Valencia, Spain 2Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain 3Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain 4Hospital Universitario Reina Sofia, Unidad Clinica de Aparato Digestivo, Cordoba, Spain 5Hospital General Universitario Alicante, Gastroenterology unit, Alicante, Spain 6Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain 7MSD Spain, Medical Department, Madrid, Spain

OP014: Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extensionECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.1, Feagan B.*2, D'Haens G.3, Levesque B.2, Pai R.4, Hanauer S.5, Wolf D.6, Vermeire S.7, Ghosh S.8, Li C.9, Penenberg D.9, Aranda R.9, Olson A.9

1University of California San Diego, San Diego, United States 2Robarts Research, London, Canada 3Academic Medical Center, Amsterdam, Netherlands 4Mayo Clinic, Department of Laboratory Medicine and Pathology, Scottsdale, United States 5Feinberg School of Medicine, Chicago, United States 6Atlanta Gastroenterology Associates, Atlanta, United States 7University of Leuven, Leuven, Belgium 8University of Calgary, Calgary, Canada 9Receptos, a wholly owned subsidiary of Celgene, San Diego, United States

OP015: Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C TRIALECCO '17 Barcelona
Year: 2017
Authors:

de Groof J.*1,2, Bemelman W.1, Eshuis E.2, Gardenbroek T.1, Bossuyt P.3, Bosmans J.4, van Dongen H.4, van Wagensveld B.5, Brink M.6, Consten E.7, Buskens C.1, D'Haens G.2, Stokkers P.8, Ponsioen C.2 LIR!C Study Group

1Academic Medical Center, Surgery, Amsterdam, Netherlands 2Academic Medical Center, Gastroenterology, Amsterdam, Netherlands 3Academic Medical Center, Epidemiology, Amsterdam, Netherlands 4VU, Health Sciences, Amsterdam, Netherlands 5OLVG West, Surgery, Amsterdam, Netherlands 6Meander Medical Center, Gastroenterology, Amersfoort, Netherlands 7Meander Medical Center, Surgery, Amersfoort, Netherlands 8OLVG West, Gastroenterology, Amsterdam, Netherlands

OP016: Potential role of bile acid receptor FXR in microscopic colitisECCO '17 Barcelona
Year: 2017
Authors:

Palmela C.*1, Torres J.1, Gomes de Sena P.2, Costa Santos M.P.1, Gouveia C.1, Oliveira M.H.2, Rodrigues C.M.P.3, Cravo M.1, Borralho P.4,5

1Hospital Beatriz Ângelo, Gastrenterology Department, Loures, Portugal 2Hospital Beatriz Ângelo, Pathology Department, Loures, Portugal 3Faculty of Pharmacy, Universidade de Lisboa, Research Institute for Medicines, Lisboa, Portugal 4Hospital Cuf Descobertas, Pathology Department, Lisboa, Portugal 5Universidade de Lisboa, Faculty of Medicine, Lisboa, Portugal

OP017: Telemedicine enables a safe shift from examination room based care to personalised care for inflammatory bowel disease: a pragmatic randomised multicenter trial with myIBDcoachECCO '17 Barcelona
Year: 2017
Authors:

de Jong M.*1,2, van der Meulen-de Jong A.3, Romberg-Camps M.4, Becx M.5, Cilissen M.1, Maljaars J.3, van Bodegraven A.4, Mahmmod N.5, Markus T.6, Hameeteman W.1, Dijkstra G.7, Masclee A.1,2, Boonen A.8,9, Jonkers D.1,2, van Tubergen A.8,9, Pierik M.1,2

1Maastricht University Medical Center (MUMC), Department of Internal Medicine, division of Gastroenterology and Hepatology, Maastricht, Netherlands 2Maastricht University Medical Center (MUMC), NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands 3Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands 4Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen, Netherlands 5St. Antonius Hospital, Department of Gastroenterology and Hepatology, Nieuwegein, Netherlands 6CCUVN, Woerden, Netherlands 7University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands 8Maastricht University Medical Center (MUMC), Department of Internal Medicine, division of Rheumatology, Maastricht, Netherlands 9Maastricht University Medical Center (MUMC), CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands

OP018: Optimal anti-TNF stop week during pregnancy depends on anti-TNF typeECCO '17 Barcelona
Year: 2017
Authors:

Kanis S., de Lima A., van der Woude C.

Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands

OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301)ECCO '17 Barcelona
Year: 2017
Authors:

Feagan B.*1, Colombel J.-F.2, Rossiter G.3, Li X.3, Usiskin K.3, Zhan X.3, Sands B.2

1Robarts Clinical Trials and University of Western Ontario, London, Canada 2Icahn School of Medicine at Mount Sinai, New York, United States 3Celgene Corporation, Summit, United States

OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Gils A.*1, Dreesen E.1, Compernolle G.1, Peeters M.1, Brouwers E.1, Tops S.1, Ballet V.2, Noman M.2, Ferrante M.2, Van Assche G.2, Vermeire S.2

1KU Leuven, P.O. Box 820 Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium 2UZ Leuven, Campus Gasthuisberg, Department of Gastroenterology and Hepatology, Leuven, Belgium

OP021: Hyperbaric oxygen therapy is safe and effective for hospitalized ulcerative colitis patients suffering from moderate-severe flares: a multi-center, randomized, double-blind, sham-controlled trialECCO '17 Barcelona
Year: 2017
Authors:

Dulai P.*1,2, Buckey Jr. J.2, Raffals L.3, Swoger J.4, Claus P.3, O'Toole K.4, Ptak J.2, Gleeson M.2, Widjaja C.1, Adler J.2, Patel N.2, Skinner L.2, Haren S.3, Goldby-Reffner K.4, Thompson K.2, Knight R.1, Chang J.1, Siegel C.2

1University of California San Diego, La Jolla, CA, United States 2Dartmouth Hitchcock Medical Center, Lebanon, NH, United States 3Mayo Clinic, Rochester, MN, United States 4University of Pittsburgh Medical Center, Pittsburgh, PA, United States

OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character studyECCO '17 Barcelona
Year: 2017
Authors:

Kalla R.*1, Adams A.1, Vatn S.2, Bergemalm D.3, Ricanek P.4, Lindstrom J.2, Ocklind A.5, Nordberg N.5, Kennedy N.1, Ventham N.1, Vatn M.4, Söderholm J.6, Pierik M.7, Törkvist L.8, Gomollόn F.9, Jahnsen J.2, Halfvarson J.3, Satsangi J.1 IBD Character Consortium, Edinburgh, United Kingdom

1University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom 2Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway 3Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden 4University of Oslo, Institute of Clinical Medicine, Oslo, Norway 5Olink Proteomics, Uppsala, Sweden 6Linköping University, Gastroenterology, Linköping, Sweden 7Maastricht University Medical Center (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands 8Karolinska Instituet, Department of Clinical Science, Intervention and Technology, Karolinska, Sweden 9HCU “Lozano Blesa”, IIS Aragόn, CIBEREHD, Zaragosa, Spain